What Is the Best Female Libido Enhancer?

There is no single best female libido enhancer. For hypoactive sexual desire disorder (HSDD), low desire that causes distress, the FDA has approved flibanserin (Addyi) for women under 65 and bremelanotide (Vyleesi) for premenopausal women. After menopause, testosterone is the only hormone option with trial evidence for HSDD, and that use is off-label. Over-the-counter "enhancers" do not have that kind of support.

Low desire is common. In a U.S. survey of 31,581 women, 43.1% reported a sexual problem and 12.0% had a sexual problem plus personal distress, with the highest rate of distressing problems at ages 45-64 (Shifren 2008).

Understanding female libido

Desire depends on hormones, mental health, relationship dynamics, medications, and life stage. A formal workup for HSDD is biopsychosocial: medical, psychological, and relationship factors are assessed together (Global Consensus 2019).

For women, those influences include:

• Hormones, including estrogen, progesterone, and testosterone

• Mental health, including depression and anxiety, which were correlates of distressing sexual problems in the U.S. survey (Shifren 2008)
• Medications, including many antidepressants. A meta-analysis found treatment-emergent sexual dysfunction in 25.8% to 80.3% of patients on several SSRIs and related drugs, and no increase versus placebo for bupropion and mirtazapine (Serretti 2009)
• Life stages, including perimenopause, menopause, and postpartum. Distressing sexual problems were most common at ages 45-64 (Shifren 2008)

Testosterone is one of those hormones. Guidelines do not treat a low female testosterone level the way they treat male hypogonadism, and testosterone is not a general treatment for low energy, mood, or focus.

So, what is the best female libido enhancer?

The internet is full of herbal pills that promise instant results. Most of those products have not been tested the way prescription options have. The useful next step is to find the cause of the low desire.

FDA-approved drugs for HSDD

Two prescription drugs are approved for acquired, generalized HSDD: low desire that developed after a period of normal desire, is not limited to one situation or partner, causes distress, and is not explained by another illness, a relationship problem, or a drug.

Flibanserin (Addyi) is a daily bedtime tablet for women under 65 with that diagnosis (Addyi label). In three 24-week randomized trials in premenopausal women (1,187 on flibanserin, 1,188 on placebo), monthly satisfying sexual events rose more than placebo by a median of 0.5 to 1.0 events. The label does not include use to enhance sexual performance. Alcohol close in time raises the risk of severe low blood pressure and fainting (boxed warning). It is contraindicated with moderate or strong CYP3A4 inhibitors and in hepatic impairment. Common reactions include dizziness, somnolence, and nausea. The label says to stop after 8 weeks if there is no improvement.

Bremelanotide (Vyleesi) is an as-needed subcutaneous injection for premenopausal women with the same HSDD diagnosis, given at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 times a month (Vyleesi label). Two 24-week Phase 3 trials showed a statistically significant rise in FSFI desire scores (mean change 0.5 and 0.6 versus 0.2 on placebo) and a drop in distress, with no significant difference in satisfying sexual events. The label does not include use after menopause, in men, or to enhance sexual performance. It is contraindicated in uncontrolled hypertension and known cardiovascular disease. Nausea occurred in 40% of patients (anti-nausea medicine in 13%; 8% stopped for nausea). Other common reactions include flushing, injection-site reactions, headache, and vomiting.

Testosterone therapy for women

A 2019 systematic review of 36 randomized trials (8,480 women) found that testosterone increased desire, arousal, orgasm, and satisfying sexual events and reduced sexual distress in postmenopausal women with low desire that caused distress (Islam 2019). Desire rose by a standardized mean difference of 0.36 versus placebo or a comparator.

The Global Consensus Position Statement, endorsed by the Endocrine Society and other societies, states that the only evidence-based indication for testosterone in women is HSDD in postmenopausal women after a formal biopsychosocial assessment (Level I, Grade A). There are not enough data to support testosterone for any other symptom, condition, or disease prevention. Use in women is off-label (Global Consensus 2019).

The same statement found no effect on general wellbeing, no clear effect on depressed mood, insufficient evidence for cognition, and no demonstrated effect of physiologic doses on bone mineral density, lean mass, or muscle strength. The meta-analysis also found no effects on body composition, musculoskeletal measures, or cognition in the trials that reported them. Acne and hair growth were more common than with placebo.

AlphaMD offers testosterone therapy for women as cream, gel, and injectables when a licensed clinician decides it fits after labs and a clinical review. For what treatment can and cannot change, see female TRT before and after. High testosterone in women is a separate condition of androgen excess.

Lifestyle changes that support libido

Exercise, sleep, and stress care belong in the same biopsychosocial picture the guidelines ask clinicians to assess (Global Consensus 2019). Depression and anxiety were already linked to distressing sexual problems in the U.S. survey (Shifren 2008).

Addressing relationship and psychological factors

The HSDD drug labels exclude desire loss that is due to problems within the relationship (Addyi label). Therapy and open communication with a partner belong in that assessment.

Beware of over-the-counter "enhancers"

Many female libido supplements make bold claims without the trial evidence behind the approved HSDD drugs or postmenopausal testosterone. Systemic DHEA has not shown a meaningful libido benefit in postmenopausal women with normal adrenal function and is not recommended for HSDD (Global Consensus 2019).

The FDA has also found hidden drug ingredients in products sold for sexual enhancement, sometimes marketed as dietary supplements or "all-natural" treatments. Those products can cause serious harm (FDA). A clinician who has the full medication list is the right person to review anything bought over the counter.

Bottom line

For HSDD, flibanserin and bremelanotide are the FDA-approved drugs, with modest trial effects and specific safety limits. After menopause, testosterone is the hormone option with randomized-trial support for distressing low desire, used off-label. It does not treat energy, mood, muscle, bone, or focus. Finding the cause still comes first.